Europe

Germany drug pricing policies are now the subject of a US Section 301 investigation. AbbVie's chief counsel, Perry Siatis, has filed written evidence and testified that government price setting, mandatory rebates and reimbursement restrictions undercut the incentives that fund new medicines. He also cites a German-French working group on keeping innovative medicines available. #SyenzaNews #MarketAccess #DrugPricing #HEOR

Mounjaro passed €1 million in pharmacy sales in a single day in Portugal, on more than 3,000 packs, and the Ordem dos Médicos has asked Infarmed for prescription data. Here is what the numbers show on access, reimbursement and supply. #SyenzaNews #GLP1 #MarketAccess

New OHE research puts the economic burden of obesity in eight European countries at 0.7% to 1.4% of GDP. Germany carries the largest bill at EUR 55.2bn; the UK carries the largest productivity share at 58%. #SyenzaAI #SyenzaNews #MarketAccess #HealthEconomics #Obesity

Syenza's webinar on AI governance in HTA drew 71% of participants who had not yet used AI in their work. The session covered the paper's governance checklist, the in-house Navigator tool, and a live rapid HTA of rituximab in lupus. #SyenzaNews #HTA #AIinHealth #MarketAccess

COMP's July 2026 sitting recommended 12 orphan drug designations, withdrew four, and sharpened the test for significant benefit against authorised therapies. #SyenzaNews #OrphanDrugs #MarketAccess #RareDiseases

Nine pharma chairs, from AstraZeneca to Sanofi, warn Europe is losing the pharmaceutical investment race to the US and China, and call on governments to treat medicines as strategic infrastructure. #SyenzaNews #pharmaceuticals #MarketAccess #drugdevelopment

The European Commission has published three templates that formalise written input from patients, carers and clinicians in EU Joint Clinical Assessments, locking it onto the scope proposal and the draft report. #HTA #JCA #MarketAccess

Portugal pharmaceutical exports climbed 42.9% in 2025 to €5.0 billion. Without that increase, national goods exports would have contracted. #SyenzaNews #MarketAccess #Pharma

Infarmed has launched INOV@INFARMED, a new network connecting Portugal's medicines regulator with 26 universities and research institutes to advance regulation and health technology assessment. #SyenzaNews #HTA #RegulatoryScience #HealthInnovation

EMA's CHMP September 2026 meeting ended with positive opinions for 12 new medicines and 11 indication extensions. New approvals cover haemophilia A, ALK-positive lung cancer, myasthenia gravis, ovarian cancer, hidradenitis suppurativa and short bowel syndrome, plus the first biosimilar cleared under the tailored clinical pathway. #SyenzaNews #pharmaceuticals #drugdevelopment #innovation #MarketAccess

NICE has reversed its earlier rejection and now recommends Enhertu (trastuzumab deruxtecan) as a routine NHS option for HER2-low metastatic breast cancer after chemotherapy. The change follows an updated commercial deal and new EQ-5D-5L utility values validated in the DESTINY-Breast04 trial. #SyenzaNews #HTA #MarketAccess #BreastCancer

Novo Nordisk and Anthropic have announced a partnership to speed drug discovery. Novo will use Claude Science across R&D and for agentic software engineering, with robust data governance and human oversight built in. #SyenzaNews #DrugDiscovery #AI #MarketAccess